🇺🇸 FDA
Patent

US 11253508

PPARy agonist for treatment of progressive supranuclear palsy

granted A61KA61K31/47A61K49/0004

Quick answer

US patent 11253508 (PPARy agonist for treatment of progressive supranuclear palsy) held by Coherus BioSciences, Inc. expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Coherus BioSciences, Inc.
Grant date
Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/47, A61K49/0004, A61P, A61P25/28